Who makes BMS-986408?

BMS-986408 is developed by Bristol-Myers Squibb.

What are the side effects of BMS-986408?

Common side effects include Diarrhoea, Anaemia, Palpitations, Adrenal insufficiency, Abdominal distension, Abdominal pain.

Last reviewed 2026-04-20 · How we verify

BMS-986408

Bristol-Myers Squibb · Phase 1 active Small molecule Quality 15/100

At a glance

Generic name	BMS-986408
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Diarrhoea
Anaemia
Palpitations
Adrenal insufficiency
Abdominal distension
Abdominal pain
Nausea
Pyrexia
Blood alkaline phosphatase increased
Blood creatinine increased
Lymphocyte count decreased
Neutrophil count decreased

Key clinical trials

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BMS-986408 CI brief — competitive landscape report
BMS-986408 updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI